A target trial emulation evaluated the incidence of emergently treated hypoalcemia associated with denosumab by stage of chronic kidney disease (CKD) progression and presence of CKD-mineral and bone disorder (CKD-MBD).
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
